Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. (RLMD) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RLMD · as of Sep 30, 2025
Ownership Breakdown
45
Institutional Holders
▼ 4 vs Q2
$15.54M
Total Inst. Value
▲ $12.36M vs Q2
73.33M
Shares Outstanding
freeFloat 82.48%
7.74M
13F Shares Held
▲ 2.44M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RLMD largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
IKARIAN CAPITAL, LLC pharmaceutical preparations | 1.84M | 5.55% | 5.55% | $3.70B | Nov 14, 2025 | ▲ 1.80M |
DRIEHAUS CAPITAL MANAGEMENT LLC pharmaceutical preparations | 740.0K | 2.23% | 2.23% | $1.49B | Nov 14, 2025 | — held |
BOOTHBAY FUND MANAGEMENT, LLC pharmaceutical preparations | 693.2K | 2.09% | 2.09% | $1.39B | Nov 14, 2025 | NEW |
ACADIAN ASSET MANAGEMENT LLC pharmaceutical preparations | 582.5K | 1.76% | 1.76% | $1.17B | Nov 13, 2025 | ▼ 36.9K |
BLACKROCK, INC. pharmaceutical preparations | 508.0K | 1.53% | 1.53% | $1.02B | Nov 12, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 418.6K | 1.26% | 1.26% | $841.35M | Nov 7, 2025 | ▲ 54.5K |
ADVISORSHARES INVESTMENTS LLC pharmaceutical preparations | 403.5K | 1.22% | 1.22% | $811.01M | Nov 5, 2025 | ▲ 7.0K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 296.2K | 89.24% | 89.24% | $595.53M | Nov 12, 2025 | ▼ 6.1K |
MARSHALL WACE, LLP pharmaceutical preparations | 272.1K | 81.96% | 81.96% | $546.83M | Nov 13, 2025 | ▲ 117.5K |
DEUTSCHE BANK AG\ pharmaceutical preparations | 224.8K | 67.74% | 67.74% | $451.94M | Nov 13, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
13
Increased
+2.23M shares4
New Positions
first time holders11
Decreased
−221.3K shares5
Sold Out
fully exitedNet shares change (top 50)
+2.01M
+2.23M / −221.3K
Net new holders
+1
4 new / 5 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RLMD insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
13
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
TRAVERSA SERGIO Chief Executive Officer | Dec 15, 2025 | Purchase | 27,500 | $4.12 | $113.3K | 1.30M | Form 4 ↗ |
TRAVERSA SERGIO Chief Executive Officer | Dec 12, 2025 | Award | 1,198,000 | $4.06 | $4.86M | 1.20M | Form 4 ↗ |
Shenouda Maged Chief Financial Officer | Dec 12, 2025 | Award | 828,000 | $4.06 | $3.36M | 828.0K | Form 4 ↗ |
Shenouda Maged Chief Financial Officer | Dec 15, 2025 | Purchase | 11,665 | $4.12 | $48.1K | 800.0K | Form 4 ↗ |
Ence Chuck CA and CO | Dec 12, 2025 | Award | 828,000 | $4.06 | $3.36M | 828.0K | Form 4 ↗ |
Fedeli Fabiana director | Dec 12, 2025 | Award | 164,000 | $4.06 | $665.8K | 164.0K | Form 4 ↗ |
GLASSPOOL JOHN director | Dec 12, 2025 | Award | 164,000 | $4.06 | $665.8K | 164.0K | Form 4 ↗ |
Kelly Paul Edward COO | Dec 12, 2025 | Award | 828,000 | $4.06 | $3.36M | 828.0K | Form 4 ↗ |
CASAMENTO CHARLES J director | Dec 12, 2025 | Award | 164,000 | $4.06 | $665.8K | 164.0K | Form 4 ↗ |
Shenouda Maged Chief Financial Officer | Nov 5, 2025 | Purchase | 500,000 | $2.20 | $1.10M | 788.3K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Relmada Therapeutics, Inc. (RLMD) is primarily owned by institutional investors, who hold approximately 10.6% of total shares outstanding. Company insiders own approximately 17.52%, while retail and public investors account for the remaining 71.93%.
The largest institutional shareholder of Relmada Therapeutics, Inc. is IKARIAN CAPITAL, LLC, holding approximately 1.84 million shares — equal to 5.55% of outstanding shares — as of September 30, 2025.
A total of 45 institutional investors currently hold RLMD stock, with a combined institutional value of approximately $15,541,689 as of the most recent 13F filing period.
Frequently asked questions
RLMD ownershipRelmada Therapeutics, Inc. (RLMD) is primarily owned by institutional investors, who hold approximately 10.6% of shares. The largest shareholder is IKARIAN CAPITAL, LLC with a 5.55% stake. Company insiders hold 17.52%. Data sourced from SEC Form 13F as of September 30, 2025.